MaxCyte Inc. | Micro-cap | Healthcare
$2.17
-2.91%
| MaxCyte Stock Comparison:
MaxCyte vs Abbott LaboratoriesMaxCyte vs Boston ScientificMaxCyte vs 908 DevicesMaxCyte vs Tactile SystemsMaxCyte vs PerspectiveMaxCyte vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 38.6M
Gross Profit 31.5M 81.62%
Operating Income -51.2M -132.54%
Net Income -41.1M -106.29%
EPS (Diluted) -$0.39

Balance Sheet Metrics

Total Assets 239.5M
Total Liabilities 33.2M
Shareholders Equity 206.3M
Debt to Equity 0.16

Cash Flow Metrics

Operating Cash Flow -24.2M
Free Cash Flow -29.3M

Revenue & Profitability Trend

MaxCyte Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue38.6M41.3M44.3M33.9M26.2M
Cost of Goods Sold7.1M4.7M5.1M3.6M2.8M
Gross Profit31.5M36.5M39.2M30.2M23.4M
Operating Expenses78.6M80.9M64.0M47.1M33.4M
Operating Income-51.2M-48.3M-27.4M-18.2M-11.1M
Pre-tax Income-41.1M-37.9M-23.6M-19.1M-11.8M
Income Tax0000-
Net Income-41.1M-37.9M-23.6M-19.1M-11.8M
EPS (Diluted)-$0.39-$0.37-$0.23-$0.21-$0.17

Income Statement Trend

MaxCyte Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets171.7M190.2M252.3M270.4M45.3M
Non-Current Assets67.8M78.1M34.4M13.7M6.5M
Total Assets239.5M268.3M286.7M284.1M51.8M
Liabilities
Current Liabilities15.8M17.9M15.4M15.6M11.6M
Non-Current Liabilities17.4M18.3M17.3M5.6M6.9M
Total Liabilities33.2M36.1M32.7M21.2M18.6M
Equity
Total Shareholders Equity206.3M232.2M254.0M262.9M33.2M

Balance Sheet Composition

MaxCyte Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income-41.1M-37.9M-23.6M-19.1M-11.8M
Operating Cash Flow-24.2M-14.8M-12.6M-9.0M-9.1M
Investing Activities
Capital Expenditures-1.7M-3.7M-18.5M-3.8M-2.1M
Investing Cash Flow6.9M55.0M-24.8M-195.0M-16.6M
Financing Activities
Dividends Paid-----
Financing Cash Flow-269.0K0231.1M28.5M
Free Cash Flow-29.3M-25.4M-33.3M-14.5M-10.9M

Cash Flow Trend

MaxCyte Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -5.68
Forward P/E -5.56
Price to Book 1.16
Price to Sales 6.12
PEG Ratio -5.56

Profitability Ratios

Profit Margin -110.92%
Operating Margin -118.34%
Return on Equity -19.63%
Return on Assets -13.12%

Financial Health

Current Ratio 12.23
Debt to Equity 9.44
Beta 1.04

Per Share Data

EPS (TTM) -$0.40
Book Value per Share $1.88
Revenue per Share $0.36

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
mxct230.7M-5.681.16-19.63%-110.92%9.44
Abbott Laboratories 231.9B17.314.7530.65%31.89%27.09
Boston Scientific 149.9B73.946.759.50%11.58%52.16
908 Devices 238.1M-3.121.49-48.15%-27.64%2.36
Tactile Systems 236.4M15.411.178.12%5.52%21.23
Perspective 256.8M-3.340.90-32.92%0.00%1.34

Financial data is updated regularly. All figures are in the company's reporting currency.